Can vaccinated donor cells fight HPV cancers? early trial begins
NCT ID NCT04713046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether immune cells from a vaccinated relative can help treat advanced HPV16-related cancers. Up to 24 patients will receive either a bone marrow transplant or a special infusion of donor immune cells. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Immune cells (CD4+ T cells) from a related donor vaccinated against HPV16, given with or without a bone marrow transplant
- What this could lead to
- If it works, this could point toward a new treatment option for advanced HPV16-related cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early, small trial (24 people) focused on safety and dosing. The treatment may not shrink tumors or could cause serious side effects like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV 16+ RECURRENT OR METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.